Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of surgical oncology|
|State||Published - Oct 1 2010|
- Postoperative complication
ASJC Scopus subject areas